2 weeks Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates Zacks

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 29.55% and 46.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?